

DPT, Confab Complete \$10M Investment

Vetter breaks ground on €70M production facility

DPT Laboratories and Confab, a DPT company specializing in complex solids, semi-solids and liquids, have completed a \$10 million investment at its sites in San Antonio and Montreal.

DPT has invested in a new compounding suite and upgrades to production filling lines in San Antonio that will increase capacity, throughput and precision. Additional upgrades include enhanced security to further restrict access to the manufacturing floor and enhance GMP compliance.

Confab expanded its R&D capabilities with a new laboratory, new equipment, and additional R&D personnel in Montreal. Confab can now offer pharmaceutical development capabilities ranging from formulation development and analytical method development to technology transfers at commercial scale.

"The investments in capital demonstrate our continuing commitment to provide high-quality development and manufacturing solutions to our partners," said Paul Josephs, senior vice president of sales, marketing and corporate development. "We are excited about the strong demand for our services and look forward to discussing our enhanced capabilities with our customers during DCAT week."

Vetter Breaks Ground on €70M Production Facility

Vetter, a global contract development and manufacturing organization (CDMO) for the development, commercial manufacturing and final packaging of aseptically prefilled drug-delivery systems, has unveiled plans for the construction of a new building at a ground breaking ceremony held at its Ravensburg Schuetzenstrasse site. Scheduled for completion in 1Q18, the building is planned to begin opera-

tions in early 2019. Expected to cost approximately €70 million (\$79 million), it is part of the total investment strategy announced in September 2015, and will constitute an important element in the overall Schuetzenstrasse facility rebuilding concept for modernization and expansion.

Upon completion, the seven-story building will cover a total of 8,000 sq. meters (86,000 sq.-ft.), and include in its core a cleanroom with supportive media systems. Additionally, it will contain the site's central material preparation; office space for the production staff as well as a staff canteen with roof garden.

The applied technology of the cleanroom will be dedicated to the filling of bulk syringes and designed to be compatible for the filling of sensitive drugs such as biologics and ophthalmics. Syringes prepared in the bulk process offer a number of customization options that are tailored to substance and primary packaging material components, and offer customizable low silicone levels and thus, process flexibility. Another central technological element of the cleanroom will be the implementation of an improved restricted access barrier system (RABS) concept to combine the advantages of isolator and RABS technology. The core of this innovative approach is a uniquely fast, by today's standards, 3-hour cycle and fully automated decontamination of the cleanroom using hydrogen peroxide (H₂O₂).

"This addition to our Schuetzenstrasse site is an exciting chapter in our company's history and will again support Vetter's target to offer its customers the adequate high manufacturing quality for their high value drugs," said Thomas Otto, managing director, Vetter. "Attaining this high level of quality is of particular significance to Vetter as it represents one of our core customer relations value propositions."

AAI/CML Now Alcami

AAI Pharma Services Corp. (AAI) / Cambridge Major Laboratories, Inc. (CML), a provider of custom development and manufacturing services for the pharma and biopharma industries, is now Alcami, representing a contemporary combination of the legacy company names. The new brand and identity provides an integrated offering for both drug substance and drug product beginning with solid state chemistry and formulation development.

AAI and CML merged in late 2013 to offer analytical testing and development services for active pharmaceutical ingredients (APIs) with oral solid and parenteral dose finished product capacity.

Alcami recently invested in additional capabilities and capacity for oral solid dose manufacturing and parenteral fill-finish, including additional sterile lines and lyophilization. Additionally, Alcami will be relocating its current St. Louis Analytical Testing Services to a new facility at the Cortex Innovation Center in St. Louis, MO, which provides analytical testing for new drug entities, generic drugs, animal health products, medicated consumer health products, chemicals and biopharmaceuticals.

Stephan Kutzer, chief executive officer, said, "With nearly 1000 employees at seven sites in the U.S. and Europe, these upgrades across our facilities in Wilmington, Charleston, Durham, Germantown, Edison, St. Louis, and Weert, the Netherlands, combined with enhancements in our quality, execution and customer focus, support the overall progress of our growth strategy as a contract services provider with a renewed commitment to meeting customer needs like never before. With increases in our capabilities and capacities across all our businesses, our ability to serve the market is stronger than ever." **CP**